Sumitomo Mitsui Trust Group Inc. Has $11.96 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Sumitomo Mitsui Trust Group Inc. trimmed its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,395 shares of the medical research company's stock after selling 1,569 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.13% of Bio-Rad Laboratories worth $11,956,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in BIO. Van ECK Associates Corp boosted its holdings in shares of Bio-Rad Laboratories by 97.8% during the third quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company's stock worth $436,861,000 after purchasing an additional 644,530 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Bio-Rad Laboratories by 1.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company's stock worth $147,583,000 after purchasing an additional 4,260 shares during the period. Westfield Capital Management Co. LP boosted its holdings in shares of Bio-Rad Laboratories by 3.9% during the third quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company's stock worth $84,571,000 after purchasing an additional 9,584 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Bio-Rad Laboratories during the third quarter worth approximately $83,681,000. Finally, Mawer Investment Management Ltd. boosted its holdings in shares of Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company's stock worth $72,900,000 after purchasing an additional 84,237 shares during the period. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on BIO shares. Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Royal Bank of Canada reaffirmed an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company cut their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $395.20.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO traded down $29.81 during trading on Friday, reaching $276.55. The stock had a trading volume of 1,065,491 shares, compared to its average volume of 151,421. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99. The firm has a market capitalization of $7.74 billion, a price-to-earnings ratio of -10.12 and a beta of 0.90. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The stock has a fifty day simple moving average of $338.72 and a two-hundred day simple moving average of $336.13.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.33 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.